July 3, 2026, 4:32 PM EDT. Asahi Kasei (TSE:3407) finished a ¥17.86 billion buyback, taking in 0.75% of its shares and signaling a focus on returns for shareholders. Peptistar has now launched Asahi Kasei's FO-MD system at the plant level, putting its pharmaceutical concentration tech into real-world production. This push could drive earnings through healthcare and process solutions, adding to its main battery and hydrogen businesses. Some risks remain for executing FO-MD and AK1940 at scale. The stock has moved up, but some see valuation still lagging-with fair value estimates pointing to a possible double from here. The story here is tighter capital discipline and a bigger bet on new technology.
